Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H43N13O10 |
| Molecular Weight | 685.69 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NCC[C@@H](O)[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)=C\NC(N)=O)[C@H]2CCNC(=N)N2
InChI
InChIKey=HPWIIERXAFODPP-GHBBWTPBSA-N
InChI=1S/C25H43N13O10/c26-3-1-16(41)10(27)5-17(42)33-12-6-31-23(47)18(11-2-4-30-24(28)37-11)38-20(44)13(7-32-25(29)48)34-21(45)14(8-39)36-22(46)15(9-40)35-19(12)43/h7,10-12,14-16,18,39-41H,1-6,8-9,26-27H2,(H,31,47)(H,33,42)(H,34,45)(H,35,43)(H,36,46)(H,38,44)(H3,28,30,37)(H3,29,32,48)/b13-7-/t10-,11-,12+,14+,15+,16-,18+/m1/s1
| Molecular Formula | C25H43N13O10 |
| Molecular Weight | 685.69 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 2 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/4308717Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/2539957 | https://www.ncbi.nlm.nih.gov/pubmed/17571483
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4308717
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/2539957 | https://www.ncbi.nlm.nih.gov/pubmed/17571483
Enviomycin, antimicrobial drug, was isolated in Japan from fermentation broth of Syteptomyces griseoverticillatus var tuberacticus. This drug, a water-soluble, basic peptide, is effective against tubercle bacilli as well as some gram-positive and gram-negative bacteria. It is related to viomycin and cepreomycin in some of its physicochemical properties. It is used for the treatment of Mycobacterium avium caused lung diseases.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0000372 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7509881 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Case of multi-drug resistant pulmonary tuberculosis with bilateral cavitary lesions successfully treated by surgical treatment]. | 2007-11 |
|
| [Case of pulmonary multi-drug resistant tuberculosis with left destroyed lung, treated with pneumonectomy]. | 2007-07 |
|
| [A case of pulmonary Mycobacterium fortuitum infection successfully treated with Kampo treatments]. | 2006-08 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2539957
1 g/day three times weekly
Route of Administration:
Unknown
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1406364
Enviomycin is bactericidal against Mycobacterium avium strain 13887 with MIC=1.6 ug/ml.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:25:12 GMT 2025
by
admin
on
Mon Mar 31 18:25:12 GMT 2025
|
| Record UNII |
XU299C23A2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3180
Created by
admin on Mon Mar 31 18:25:12 GMT 2025 , Edited by admin on Mon Mar 31 18:25:12 GMT 2025
|
PRIMARY | |||
|
100000080241
Created by
admin on Mon Mar 31 18:25:12 GMT 2025 , Edited by admin on Mon Mar 31 18:25:12 GMT 2025
|
PRIMARY | |||
|
CHEMBL2146142
Created by
admin on Mon Mar 31 18:25:12 GMT 2025 , Edited by admin on Mon Mar 31 18:25:12 GMT 2025
|
PRIMARY | |||
|
m4924
Created by
admin on Mon Mar 31 18:25:12 GMT 2025 , Edited by admin on Mon Mar 31 18:25:12 GMT 2025
|
PRIMARY | Merck Index | ||
|
XU299C23A2
Created by
admin on Mon Mar 31 18:25:12 GMT 2025 , Edited by admin on Mon Mar 31 18:25:12 GMT 2025
|
PRIMARY | |||
|
33103-22-9
Created by
admin on Mon Mar 31 18:25:12 GMT 2025 , Edited by admin on Mon Mar 31 18:25:12 GMT 2025
|
PRIMARY | |||
|
SUB06554MIG
Created by
admin on Mon Mar 31 18:25:12 GMT 2025 , Edited by admin on Mon Mar 31 18:25:12 GMT 2025
|
PRIMARY | |||
|
Enviomycin
Created by
admin on Mon Mar 31 18:25:12 GMT 2025 , Edited by admin on Mon Mar 31 18:25:12 GMT 2025
|
PRIMARY | |||
|
DTXSID901027569
Created by
admin on Mon Mar 31 18:25:12 GMT 2025 , Edited by admin on Mon Mar 31 18:25:12 GMT 2025
|
PRIMARY | |||
|
DB08993
Created by
admin on Mon Mar 31 18:25:12 GMT 2025 , Edited by admin on Mon Mar 31 18:25:12 GMT 2025
|
PRIMARY | |||
|
3577
Created by
admin on Mon Mar 31 18:25:12 GMT 2025 , Edited by admin on Mon Mar 31 18:25:12 GMT 2025
|
PRIMARY | |||
|
C169954
Created by
admin on Mon Mar 31 18:25:12 GMT 2025 , Edited by admin on Mon Mar 31 18:25:12 GMT 2025
|
PRIMARY | |||
|
20055267
Created by
admin on Mon Mar 31 18:25:12 GMT 2025 , Edited by admin on Mon Mar 31 18:25:12 GMT 2025
|
PRIMARY | |||
|
D004776
Created by
admin on Mon Mar 31 18:25:12 GMT 2025 , Edited by admin on Mon Mar 31 18:25:12 GMT 2025
|
PRIMARY | |||
|
m11253
Created by
admin on Mon Mar 31 18:25:12 GMT 2025 , Edited by admin on Mon Mar 31 18:25:12 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |